Bernstein initiated coverage of Kenvue (KVUE) with an Underperform rating and $18 price target. Kenvue – the former Johnson & Johnson (JNJ) Consumer Health business – has consistently lost market share across the majority of its business for the past several years, says the analyst, who expects FY24 investment to prove “inadequate” and struggles to see “a path to share stabilization absent significant further re-investment.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE: